The amount of expense for licensing agreements.

No definition available.

Name:	mbrx_LicenseAgreementsExpense
Namespace Prefix:	mbrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The amount of license terminations expense.

+ References

No definition available.

+ Details

Name:	mbrx_LicenseTerminationsExpense
Namespace Prefix:	mbrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The cancellation period for other commitments.

+ References

No definition available.

+ Details

Name:	mbrx_OtherCommitmentsCancellationPeriod
Namespace Prefix:	mbrx_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

The number of agreements of other commitments.

+ References

No definition available.

+ Details

Name:	mbrx_OtherCommitmentsNumberOfAgreements
Namespace Prefix:	mbrx_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Represents payments for research and development agreement.

+ References

No definition available.

+ Details

Name:	mbrx_PaymentsForResearchAndDevelopmentAgreement
Namespace Prefix:	mbrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The amount of cash outflow for the termination of a commitment.

+ References

No definition available.

+ Details

Name:	mbrx_PaymentsForTerminationOfCommitment
Namespace Prefix:	mbrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 5
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (g)(1)
-URI https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980

+ Details

Name:	us-gaap_OperatingLeasePayments
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.

+ References

No definition available.

+ Details

Name:	us-gaap_OtherCommitment
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

+ Details

Name:	us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 912
-SubTopic 730
-Section 25
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of sublease income excluding finance and operating lease expense.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971

+ Details

Name:	us-gaap_SubleaseIncome
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mbrx_HoustonPharmaceuticalsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_OtherCommitmentsAxis=mbrx_ConsultingAgreementOnLicensedMoleculesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_OtherCommitmentsAxis=mbrx_AgreementProvidingAccessToLaboratoryEquipmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=mbrx_MdAndersonMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=mbrx_DerminMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Note 7 - Commitments and Contingencies (Details Textual)		1 Months Ended		3 Months Ended
	Mar. 16, 2020 USD ($)	Feb. 28, 2022 USD ($)	Jul. 31, 2021 USD ($)	Mar. 31, 2022 USD ($)	Mar. 31, 2021 USD ($)
Sublease Income				$ 10,000	$ 10,000
Operating Lease, Payments				35,000	34,000
Research and Development Expense, Total				4,620,000	4,105,000
Houston Pharmaceuticals, Inc [Member]
Related Party Transaction, Expenses from Transactions with Related Party				59,000	59,000
Houston Pharmaceuticals, Inc [Member] \| Consulting Agreement on Licensed Molecules [Member]
Other Commitments, Number of Agreements	2
Other Commitment, Total	$ 43,500
Houston Pharmaceuticals, Inc [Member] \| Agreement Providing Access to Laboratory Equipment [Member]
Other Commitment, Total	$ 15,000
Other Commitments, Cancellation Period (Day)	60 days
MD Anderson [Member]
License Agreements Expense				76,000	38,000
Payments For Research And Development Agreement			$ 175,000
Research and Development Expense, Total				187,000	94,000
Dermin [Member]
Payments for Termination of Commitment		$ 400,000
License Terminations Expense				$ 400,000	$ 0